Mitomycin C does not inhibit exacerbation of granular corneal dystrophy type II induced by refractive surface ablation.
To evaluate the effect of mitomycin C (MMC) on the exacerbation of corneal opacity that occurs in patients with granular corneal dystrophy type II (GCD II) after refractive corneal surface ablation. Ten eyes of patients with GCD II who underwent refractive corneal surface ablation with MMC were compared with 10 eyes that were not treated with MMC. Best spectacle-corrected visual acuity, the degree of corneal opacity, and contrast sensitivity were evaluated at least 3 years after surgery. Corneal opacities were quantified using Pentacam densitometry maps. No measured between-group value showed a statistically significant difference. Simultaneous application of MMC does not prevent exacerbation of GCD II after refractive corneal surface ablation.